BioCentury
ARTICLE | Clinical News

Agilect rasagiline regulatory update

July 12, 2004 7:00 AM UTC

TEVA received an FDA approvable letter for Agilect rasagiline to treat Parkinson's disease (PD). The irreversible selective inhibitor of the monoamine oxide B ( MAO-B) is under review in Europe. ...